{"id":1602,"date":"2026-03-15T21:58:46","date_gmt":"2026-03-15T21:58:46","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/03\/15\/the-c-world-needs-funding\/"},"modified":"2026-03-15T21:58:46","modified_gmt":"2026-03-15T21:58:46","slug":"the-c-world-needs-funding","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/03\/15\/the-c-world-needs-funding\/","title":{"rendered":"The C world needs funding"},"content":{"rendered":"<div class=\"twitter-share\"><a href=\"https:\/\/twitter.com\/intent\/tweet?url=https%3A%2F%2Fmultiple-sclerosis-research.org%2F2026%2F03%2Fthe-c-world-needs-funding%2F&#038;via=the_MSBlog\" class=\"twitter-share-button\" data-size=\"large\">Tweet<\/a><\/div>\n<p>The C word&#8230;.is often mentioned when it comes to MS&#8230;but proof-is in the  pudding. If MS is an autoimmune condion and you know how to turn the immune system off you can silence autoimmunity&#8230;I have done it. <\/p>\n<p>But the isssue is how do you translate it into controling MS, when you don&#8217;t really know the precise target. You can take a guess but you only know you get it right, when it works but the danger is it doesn&#8217;t work because you didn&#8217;t know how to do the test. So far we have lots of similar claims and the ideas have all ended up on the maggot pile. I would argue there are many claims that don&#8217;t hold water but we have a a paper entitled<\/p>\n<p>entitled: Assessing the Early Economic Feasibility of a <strong>Curative Gene Therapy<\/strong> for Multiple Sclerosis&#8230;Healthcare. 2026; 14:674.\u00a0<\/p>\n<p>This perhaps is a follow on from an earlier upbeat publication &#8220;Early-stage health technology assessment of a curative gene therapy for multiple sclerosis&#8221; in 2024. Their concluding comments<\/p>\n<p>..&#8221;gene therapy shows promising cost-effectiveness at a value-based price up to approximately \u20ac500\u2009000, contingent on achieving curative clinical efficacy. These findings inform strategic development and pricing considerations for emerging gene therapies in MS&#8221;.<\/p>\n<p>In 2026 they say &#8220;&#8230;.Structural gap between value-based pricing and the pricing required for commercial viability. Without external support or reductions in cost structures, commercial development may be economically unattractive.<\/p>\n<p>I seem to read this as a cry for support.<\/p>\n<p>It is very hard for academics to deliver new treatments and it requires alot of cash. For MS it is hard to do anything unless you have big pharma support&#8230;I could look and comment on the biology but I won&#8217;t&#8230;they are making big claims of the &#8220;c&#8221;. I would think it is much easier to do this in other conditions than MS.<\/p>\n<p>To do a phase III trial needs big pharma input. It isn&#8217;t really ethical to do placebo control led trials in relapsing MS, so you need to buy the comparitor treatment. So say 600 people on a drug costing $100,000 a year for 2 years and so that is $120,000,000 to find before you get your new C to market. <\/p>\n<p>CoI None<\/p>\n<p>Disclaimer. My views<\/p>\n<p><em>Source: <a href=\"https:\/\/multiple-sclerosis-research.org\/2026\/03\/the-c-world-needs-funding\/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-c-world-needs-funding\" rel=\"nofollow noopener\" target=\"_blank\">multiple-sclerosis-research.org<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tweet The C word&#8230;.is often mentioned when it comes to MS&#8230;but proof-is in the pudding. If MS is an autoimmune condion and you know how to turn the immune system off you can silence autoimmunity&#8230;I have done it. But the isssue is how do you translate it into controling MS, when you don&#8217;t really know&#8230;<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-1602","post","type-post","status-publish","format-standard","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=1602"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1602\/revisions"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=1602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=1602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=1602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}